The government and Eli Lilly have committed £85 million to twelve technology-driven obesity care projects across the UK, from AI triage in East Anglia to round-the-clock WhatsApp coaching in Kent.

Twelve Regions, One Ambition Can the UK Finally Fix How It Treats Obesity?

Britain has known for years that its approach to obesity care is broken. The specialist clinics are oversubscribed. The referral routes are fragmented. And the people most likely to need help, those in deprived coastal towns, rural communities, or minority ethnic populations with historically poor access to NHS services, are the least likely to get it. What has been missing is not evidence of the problem. It is a coordinated, funded will to do something structurally different about it.

That, at least, is what the Obesity Pathway Innovation Programme(OPIP) is designed to provide. Announced on 27th June, OPIP funds twelve projects across all four nations, backed by £50 million from the government and up to £35 million from Eli Lilly. James Murray, Secretary of State for Health and Social Care, did not mince his words at the launch. He said, “Obesity is an epidemic and we need bold action to end it now.” The numbers support the urgency. Almost one in three adults across England, Scotland, and Northern Ireland are living with the condition. The NHS spends more than £9 billion a year managing it. Across UK society, the estimated cost runs to £107 billion annually.

The twelve projects funded under OPIP will not solve that on their own. They are not designed to. What they are designed to do is test new models of care, using technology to extend clinical reach, reduce access barriers, and generate the evidence base needed to reshape obesity services nationally after the programme concludes in March 2029.

Technology as the Access Route, Not the Destination

What distinguishes OPIP from previous digital health initiatives is that the technology is framed as a means of access rather than an end in itself. No single platform is being rolled out nationally. Instead, each project deploys whatever combination of tools fits its population and geography, with community co-design built in and clinical oversight retained throughout.

In Kent and Medway, 3,300 families will be supported from pregnancy through early childhood via an AI-powered WhatsApp service operating around the clock, in over twenty languages, with voice note functionality for users who find reading difficult. A parent in the middle of the night, anxious about their toddler’s diet and unable to reach a GP, can get a clinically grounded response without leaving the house. Women requiring more intensive support can be escalated to a specialist team including an obesity clinician, psychologist, and dietitian, exactly the kind of joined-up expertise that has until now been largely inaccessible in the most deprived parts of Medway.

In Norfolk, north east Essex, and Suffolk, up to 85,270 patients over three years will pass through a single unified service where AI matches them to the right tier of support, digital education, dietary advice, behavioural intervention, or specialist care. New neighbourhood hubs and community pharmacy partnerships sit alongside the digital pathway for those with the greatest clinical need. In Birmingham, Solihull, and the Black Country, the BRIDGE project offers access in over eighteen languages and explicitly targets people living with serious mental illness, those on orthopaedic waiting lists, and young people with severe obesity, groups that weight management services have historically struggled to engage, let alone retain.

Scotland fields two projects with notably different characters. Lanarkshire’s co-designed digital platform is built to flex across obesity, type 2 diabetes prevention, and cardiovascular risk reduction, treating these as overlapping conditions rather than siloed referral categories. The Midlothian LIMITLESS STRIDE programme connects NHS Lothian’s existing health app infrastructure with a parallel pathway for Armed Forces personnel through the Defence Medical Command, designed to remain functional across postings and deployments.

Meet People Where They Are But the Hard Part Is Staying There

Liz Kendall, Secretary of State for Science, Innovation and Technology, framed the programme’s ambition directly. She said the projects will “meet people where they are, whether that is through a pharmacy round the corner, an app on their phone, or support in their own language.” For communities that have historically been invisible to NHS weight management services, that framing matters. Wales delivers its first fully integrated national obesity care pathway through OPIP, with a bilingual digital entry point removing the postcode lottery that has long determined whether Welsh speakers could access equivalent support to English-language users. Lincolnshire receives specialist obesity provision for the first time, ending a situation where patients had to leave the county entirely for clinical-grade care.

Professor Naveed Sattar, Chair of the Obesity Healthcare Goals, described the investment as “very encouraging.” He added: “Each project brings distinct strengths and will explore innovative approaches to care, with the most successful strategies likely to shape future obesity services across the UK.” Professor Ben Bridgewater, Executive Chair of the Health Innovation Network, called it “a collective leadership opportunity.” He said: “This is an example of partners, industry, national and devolved governments and the NHS aligning priorities to deliver innovation locally, closer to patients, that will have a national impact, improving health and wealth across the country.”

The Health Innovation Network will lead a Communities of Practice framework to capture learning across all twelve projects and feed it back into the system in real time, an attempt to avoid the isolation that has undermined previous pilot programmes.

The Eli Lilly Question

It would be journalistically negligent not to examine the role of Eli Lilly in this programme. The world’s largest pharmaceutical company contributed up to £35 million in grant funding and worked with DSIT and Innovate UK to design the programme’s eligibility guidelines, before being formally excluded from the assessment and selection process. The government is explicit that Lilly had no role in determining which projects were funded.

What cannot be set aside is the commercial context. Lilly manufactures tirzepatide, one of the most significant obesity medicines currently available, and stands to benefit substantially if OPIP normalises pharmaceutical treatment as a component of NHS obesity pathways. The programme does include medication as an option “where clinically appropriate,” which is the correct clinical framing, but one that will require genuinely independent scrutiny as evaluation data emerges. Chris Stokes, President and General Manager of Lilly UK and Northern Europe, said the company was “proud to work with the government to support NHS partners in projects which have the potential to modernise obesity services and make a genuine difference in the lives of people living with obesity.” That may be true. It is also, transparently, good business.

What March 2029 Will Actually Tell Us

The programme runs for three years. What it proves in that time, about clinical outcomes, equity of access, cost-effectiveness, and population reach, will determine whether OPIP becomes a template for national transformation or another well-intentioned pilot that the mainstream commissioning system was never quite ready to absorb.

The history of NHS digital health is not short of promising innovations that expired quietly when their grant funding did. What would make OPIP genuinely different is not the WhatsApp bots or the AI triage tools, which are not especially novel, but the policy infrastructure being built around them. If ICBs and devolved health boards use the next three years to prepare commissioning frameworks for what comes after, there is a credible path to durable change. If the evaluation sits on a shelf while the next funding cycle arrives, the country will have spent £85 million learning something it already suspected: that community-based obesity care, done properly, works. That is not nothing. But it is not enough.